CONCORDBIO.NS Concord Biotech Ltd.
Price history
Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.
Technical indicators
ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.
MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.
Delivery volume
| Date | Traded Qty | Delivery Qty | Delivery % |
|---|---|---|---|
| 2026-08-28 | 88034 | 40010 | 45.45% |
| 2026-08-27 | 184371 | 90910 | 49.31% |
| 2026-08-26 | 55487 | 27069 | 48.78% |
| 2026-08-25 | 53615 | 25252 | 47.10% |
| 2026-08-24 | 141913 | 56671 | 39.93% |
| 2026-08-21 | 94192 | 32018 | 33.99% |
| 2026-08-20 | 146782 | 50591 | 34.47% |
| 2026-08-19 | 194664 | 84179 | 43.24% |
| 2026-08-18 | 489172 | 167748 | 34.29% |
| 2026-08-17 | 599262 | 219965 | 36.71% |
| 2026-08-14 | 115788 | 64989 | 56.13% |
| 2026-08-13 | 110289 | 53035 | 48.09% |
| 2026-08-12 | 93615 | 42500 | 45.40% |
| 2026-08-11 | 274179 | 100094 | 36.51% |
| 2026-08-10 | 360086 | 104632 | 29.06% |
| 2026-08-07 | 68791 | 32434 | 47.15% |
| 2026-08-06 | 112184 | 53666 | 47.84% |
| 2026-08-05 | 99717 | 50997 | 51.14% |
| 2026-08-04 | 246334 | 109934 | 44.63% |
| 2026-08-03 | 402980 | 168692 | 41.86% |
Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers CONCORDBIO.NS to fetch more history.
Insider trading activity
| Disclosed | Person | Category | Type | Mode | Quantity | Value (₹) | Resulting stake | |
|---|---|---|---|---|---|---|---|---|
| 23 Sep 2024 | Chandrashekhar Mukundrao Chawan | - | Sell | Market Sale | 1000 | 2109400 | 0.01% | XBRL |
| 23 Sep 2024 | Prakash Lalchand Sajnani | - | Sell | Market Sale | 5000 | 10844008 | 0.02% | XBRL |
| 04 Sep 2024 | Devang Bhatt | - | Sell | Market Sale | 3000 | 5204357 | 0.01% | XBRL |
| 13 Jun 2024 | Kanishka Kapoor | Immediate relative | Sell | Market Sale | 10000 | 144040200 | 0.00% | XBRL |
| 05 Jun 2024 | Ravi Kapoor | Director | Sell | Gift | 10000 | 0 | 0.20% | XBRL |
| 27 Feb 2024 | Raksha Modi | Immediate relative | Sell | Market Sale | 2000 | 2984731 | 0.02% | XBRL |
| 27 Feb 2024 | Rajendra Modi | - | Sell | Market Sale | 4000 | 5998089 | 0.02% | XBRL |
| 22 Nov 2023 | UTPAL SHETH | Other | Buy | Market Purchase | 253 | 311449 | 0.00% | XBRL |
| 21 Nov 2023 | UTPAL SHETH | Other | Buy | Market Purchase | 1468 | 1937488 | 0.00% | XBRL |
SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers CONCORDBIO.NS to fetch more.
Extract this company (financials + ratios + citations): CSV · XLSX
Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score
Ratios
This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.
Growth & earnings trend
Revenue & Profit CAGR
Operating Margin Trend
Eroding
ROCE Trajectory
Earnings Quality
No persistent gap detected
Net Profit CAGR -7.98% vs CFO CAGR 0.27% over 2.0y (2024-03-31 → 2026-03-31); most recent year: Net Profit -29.80% vs CFO +9.15%
Sector-Relative Percentile (Healthcare)
Quarterly trend
| Metric (to shareholders basis) | Q4 FY2023-24 | Q1 FY2024-25 | Q2 FY2024-25 | Q3 FY2024-25 | Q4 FY2024-25 | Q1 FY2025-26 | Q2 FY2025-26 | Q3 FY2025-26 | Q4 FY2025-26 | Q1 FY2026-27 | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹318.97 Cr. | ₹215.80 Cr. | ₹310.18 Cr. | ₹244.22 Cr. | ₹429.88 Cr. | ₹203.99 Cr. | ₹247.06 Cr. | ₹277.77 Cr. | ₹326.08 Cr. | ₹257.49 Cr. | RevenueFromOperations |
| Net Profit | ₹95.02 Cr. | ₹59.59 Cr. | ₹95.74 Cr. | ₹75.92 Cr. | ₹140.39 Cr. | ₹44.06 Cr. | ₹63.58 Cr. incl. minority ₹63.06 Cr. | ₹64.48 Cr. incl. minority ₹63.64 Cr. | ₹88.79 Cr. incl. minority ₹88.47 Cr. | ₹58.53 Cr. incl. minority ₹57.70 Cr. | ProfitOrLossAttributableToOwnersOfParent |
Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers CONCORDBIO.NS to fetch more.
Source document — income statement (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| ProfitOrLossAttributableToOwnersOfParent | 2609059000.0 |
| PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital | 104616000.0 |
Source document — balance sheet (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| CurrentAssets | 12501117000.0 |
| CurrentLiabilities | 1690771000.0 |
| EquityAttributableToOwnersOfParent | 20170613000.0 |
| BorrowingsCurrent + BorrowingsNoncurrent | — |